THE KINETIC RELEASE AND In-vivo STUDY OF ALGINATECHITOSAN ENCAPSULATED METFORMIN AGAINST TYPE II DIABETES MELLITUS

Abstract

This study was a purpose to determine the kinetic release of metformin encapsulated in chitosan alginate and to determine the antidiabetic effectiveness by in vivo study. Encapsulation of metformin was carried out by using alginate and chitosan polymers with CaCl2 as a crosslinking agent and Tween 80 as a surfactant. A total of 30 mice were divided into 6 groups, namely the normal group with distilled water, the positive control group with metformin without encapsulation, the negative control group with Na-CMC (without drug treatment), and the treatment group (encapsulated drug with a composition of 1:1; 1:2; and 1:3). Substances used for diabetes include intraperitoneally induced alloxan monohydrate. The results showed the release of metformin in pH 1.2 of the gastric physiological solution. The mechanism is followed the Korsmeyer Peppas equation. In the intestinal physiological solution pH, 7.4 followed the Higuchi equation with the mechanism was an erosion. The analysis of surface morphology of metformin encapsulated showed agglomeration in several parts on the surface of the encapsulated metformin matrix without the addition of Tween 80 surfactant. Meanwhile, the SEM results of encapsulated metformin with the addition of surfactant Tween 80 have a smooth matrix surface and there is no agglomeration. In vivo test showed there was a decrease in blood sugar in the optimum composition of metformin encapsulation with a 1:2 ratio of 37.9 mg/dl.